https://www.aiom.it/en/ 2025-02-14T15:41:06+00:00 https://www.aiom.it/en/asco-aiom-international-clinical-research-course/ 2023-04-06T15:41:29+00:00 https://www.aiom.it/en/privacy-cookie/ 2019-05-16T15:17:07+00:00 https://www.aiom.it/en/legal/ 2019-05-16T15:16:36+00:00 https://www.aiom.it/en/quality-certifications/ 2019-05-16T15:15:41+00:00 https://www.aiom.it/en/members-area/ 2019-09-26T09:36:47+00:00 https://www.aiom.it/en/meetings/ 2024-04-05T09:41:39+00:00 https://www.aiom.it/en/contact-us/ 2024-04-05T09:46:57+00:00 https://www.aiom.it/en/cancer-figures-in-italy/ 2024-04-05T10:12:19+00:00 https://www.aiom.it/en/clinical-trials-in-italy/ 2024-04-05T09:44:06+00:00 https://www.aiom.it/en/aiom-scientific-publications/ 2023-10-02T13:30:19+00:00 https://www.aiom.it/en/rule-book/ 2019-05-16T14:00:48+00:00 https://www.aiom.it/en/presentation-of-the-activities-and-of-the-society/ 2024-04-05T09:46:03+00:00 https://www.aiom.it/en/statute/ 2019-09-25T08:49:57+00:00 https://www.aiom.it/en/linee-guida-aiom/ 2023-04-07T11:18:19+00:00 https://www.aiom.it/en/upfront-modified-folfoxiri-plus-panitumumab-for-ras-braf-wild-type-metastatic-colorectal-cancer-final-results-of-the-phase-iii-triplete-study/ 2026-02-19T08:15:13+00:00 https://www.aiom.it/en/neoadjuvant-ctla-4-pd-l1-blockade-versus-surgery-chemotherapy-in-deficient-mismatch-repair-microsatellite-instability-high-resectable-gastroesophageal-adenocarcinoma-individual-patient-data-poo/ 2026-02-11T14:43:19+00:00 https://www.aiom.it/en/trastuzumab-deruxtecan-plus-pertuzumab-for-her2-positive-metastatic-breast-cancer/ 2025-12-03T09:38:26+00:00 https://www.aiom.it/en/the-impact-of-concordance-between-liquid-and-tissue-biopsy-for-actionable-mutations-insights-from-the-rome-trial/ 2025-10-10T11:40:40+00:00 https://www.aiom.it/en/zanidatamab-plus-chemotherapy-as-first-line-treatment-for-patients-with-her2-positive-advanced-gastro-oesophageal-adenocarcinoma-primary-results-of-a-multicentre-single-arm-phase-2-study/ 2025-10-03T07:31:38+00:00 https://www.aiom.it/en/nivolumab-plus-ipilimumab-versus-lenvatinib-or-sorafenib-as-first-line-treatment-for-unresectable-hepatocellular-carcinoma-checkmate-9dw-an-open-label-randomised-phase-3-trial/ 2025-07-30T14:18:18+00:00 https://www.aiom.it/en/relacorilant-and-nab-paclitaxel-in-patients-with-platinum-resistant-ovarian-cancer-rosella-an-open-label-randomised-controlled-phase-3-trial/ 2025-07-28T14:02:50+00:00 https://www.aiom.it/en/overall-survival-with-inavolisib-in-pik3ca-mutated-advanced-breast-cancer/ 2025-07-21T07:17:44+00:00 https://www.aiom.it/en/avelumab-plus-sacituzumab-govitecan-versus-avelumab-monotherapy-as-first-line-maintenance-treatment-in-patients-with-advanced-urothelial-carcinoma-javelin-bladder-medley-interim-analysis/ 2025-07-11T10:06:03+00:00 https://www.aiom.it/en/encorafenib-cetuximab-and-mfolfox6-in-braf-mutated-colorectal-cancer/ 2025-07-03T07:24:22+00:00 https://www.aiom.it/en/structured-exercise-after-adjuvant-chemotherapy-for-colon-cancer/ 2025-06-30T07:44:22+00:00 https://www.aiom.it/en/vepdegestrant-a-protac-estrogen-receptor-degrader-in-advanced-breast-cancer/ 2025-06-23T07:29:19+00:00 https://www.aiom.it/en/overall-survival-analysis-of-the-phase-iii-codebreak-300-study-of-sotorasib-plus-panitumumab-versus-investigators-choice-in-chemorefractory-kras-g12c-colorectal-cancer/ 2025-05-22T07:32:28+00:00 https://www.aiom.it/en/prognostic-implications-of-risk-definitions-from-the-monarche-and-natalee-trials/ 2025-05-19T08:04:14+00:00 https://www.aiom.it/en/camrelizumab-vs-placebo-in-combination-with-chemotherapy-as-neoadjuvant-treatment-in-patients-with-early-or-locally-advanced-triple-negative-breast-cancer-the-camrelief-randomized-clinical-trial/ 2025-05-08T13:54:12+00:00 https://www.aiom.it/en/perioperative-chemotherapy-or-preoperative-chemoradiotherapy-in-esophageal-cancer/ 2025-03-28T08:30:18+00:00 https://www.aiom.it/en/neoadjuvant-and-adjuvant-osimertinib-in-stage-ia-to-iiia-egfr-mutant-nsclc-nora/ 2025-03-21T08:32:02+00:00 https://www.aiom.it/en/three-year-overall-survival-with-nivolumab-plus-relatlimab-in-advanced-melanoma-from-relativity-047/ 2025-03-05T15:57:27+00:00 https://www.aiom.it/en/neoadjuvant-nivolumab-and-chemotherapy-in-early-estrogen-receptor-positive-breast-cancer-a-randomized-phase-3-trial/ 2025-02-27T08:40:14+00:00 https://www.aiom.it/en/encorafenib-cetuximab-and-chemotherapy-in-braf-mutant-colorectal-cancer-a-randomized-phase-3-trial/ 2025-02-20T12:15:11+00:00 https://www.aiom.it/en/thermal-ablation-versus-surgical-resection-of-small-size-colorectal-liver-metastases-collision-an-international-randomised-controlled-phase-3-non-inferiority-trial/ 2025-02-13T08:15:13+00:00 https://www.aiom.it/en/imlunestrant-with-or-without-abemaciclib-in-advanced-breast-cancer/ 2025-02-10T13:47:40+00:00 https://www.aiom.it/en/trastuzumab-pertuzumab-plus-eribulin-or-taxane-as-first-line-chemotherapy-for-human-epidermal-growth-factor-2-positive-locally-advanced-metastatic-breast-cancer-the-randomized-noninferiority-phase-ii/ 2025-01-30T08:59:01+00:00 https://www.aiom.it/en/axillary-surgery-in-breast-cancer-primary-results-of-the-insema-trial/ 2025-01-27T08:48:24+00:00 https://www.aiom.it/en/a-randomized-study-of-6-versus-3-years-of-adjuvant-imatinib-in-patients-with-localized-gist-at-high-risk-of-relapse/ 2024-11-25T09:00:58+00:00 https://www.aiom.it/en/an-open-label-study-of-pemigatinib-in-cholangiocarcinoma-final-results-from-fight-202/ 2024-09-13T07:59:33+00:00 https://www.aiom.it/en/cigarette-smoking-and-e-cigarette-use-induce-shared-dna-methylation-changes-linked-to-carcinogenesis/ 2024-09-09T07:33:44+00:00 https://www.aiom.it/en/perioperative-nivolumab-in-resectable-lung-cancer/ 2024-08-02T07:32:45+00:00 https://www.aiom.it/en/amivantamab-plus-lazertinib-in-previously-untreated-egfr-mutated-advanced-nsclc/ 2024-07-26T07:41:26+00:00 https://www.aiom.it/en/neoadjuvant-immunotherapy-in-locally-advanced-mismatch-repair-deficient-colon-cancer/ 2024-07-11T13:38:31+00:00 https://www.aiom.it/en/neoadjuvant-nivolumab-and-ipilimumab-in-resectable-stage-iii-melanoma/ 2024-07-05T10:02:48+00:00 https://www.aiom.it/en/overall-survival-with-adjuvant-pembrolizumab-in-renal-cell-carcinoma/ 2024-07-03T10:43:33+00:00 https://www.aiom.it/en/the-partner-trial-of-neoadjuvant-olaparib-with-chemotherapy-in-triple-negative-breast-cancer/ 2024-06-10T06:48:22+00:00 https://www.aiom.it/en/final-results-from-the-randomized-phase-iii-ascent-clinical-trial-in-metastatic-triple-negative-breast-cancer-and-association-of-outcomes-by-human-epidermal-growth-factor-receptor-2-and-trophoblast-ce/ 2024-06-03T08:42:52+00:00 https://www.aiom.it/en/pembrolizumab-or-placebo-with-chemoradiotherapy-followed-by-pembrolizumab-or-placebo-for-newly-diagnosed-high-risk-locally-advanced-cervical-cancer-engot-cx11-gog-3047-keynote-a18-a-randomised-d/ 2024-05-24T07:12:13+00:00 https://www.aiom.it/en/translational-and-therapeutic-evaluation-of-ras-gtp-inhibition-by-rmc-6236-in-ras-driven-cancers/ 2024-05-10T07:52:35+00:00 https://www.aiom.it/en/ribociclib-plus-endocrine-therapy-in-early-breast-cancer/ 2024-04-18T07:47:55+00:00 https://www.aiom.it/en/enfortumab-vedotin-and-pembrolizumab-in-untreated-advanced-urothelial-cancer/ 2024-04-10T14:32:55+00:00 https://www.aiom.it/en/final-analysis-of-phase-ii-results-with-cemiplimab-in-metastatic-basal-cell-carcinoma-after-hedgehog-pathway-inhibitors/ 2024-04-04T07:36:15+00:00 https://www.aiom.it/en/four-year-overall-survival-update-from-the-phase-iii-himalaya-study-of-tremelimumab-plus-durvalumab-in-unresectable-hepatocellular-carcinoma/ 2024-03-27T15:53:05+00:00 https://www.aiom.it/en/international-pooled-analysis-of-leisure-time-physical-activity-and-premenopausal-breast-cancer-in-women-from-19-cohorts/ 2024-03-25T09:01:52+00:00 https://www.aiom.it/en/osimertinib-with-or-without-chemotherapy-in-egfr-mutated-advanced-nsclc/ 2024-03-15T08:23:01+00:00 https://www.aiom.it/en/fluorouracil-leucovorin-and-irinotecan-plus-cetuximab-versus-cetuximab-as-maintenance-therapy-in-first-line-therapy-for-ras-and-braf-wild-type-metastatic-colorectal-cancer-phase-iii-ermes-study/ 2024-03-08T13:15:35+00:00 https://www.aiom.it/en/pregnancy-after-breast-cancer-in-young-brca-carriers-an-international-hospital-based-cohort-study/ 2024-02-16T15:37:22+00:00 https://www.aiom.it/en/nivolumab-plus-gemcitabine-cisplatin-in-advanced-urothelial-carcinoma/ 2024-02-09T08:19:40+00:00 https://www.aiom.it/en/tarlatamab-for-patients-with-previously-treated-small-cell-lung-cancer/ 2024-01-22T09:32:37+00:00 https://www.aiom.it/en/biomarker-data-from-the-phase-iii-katherine-study-of-adjuvant-t-dm1-versus-trastuzumab-for-residual-invasive-disease-after-neoadjuvant-therapy-for-her2-positive-breast-cancer/ 2024-01-15T07:47:48+00:00 https://www.aiom.it/en/nalirifox-versus-nab-paclitaxel-and-gemcitabine-in-treatment-naive-patients-with-metastatic-pancreatic-ductal-adenocarcinoma-napoli-3-a-randomised-open-label-phase-3-trial/ 2024-01-02T08:19:37+00:00 https://www.aiom.it/en/three-year-overall-survival-with-tebentafusp-in-metastatic-uveal-melanoma/ 2023-12-14T10:50:14+00:00 https://www.aiom.it/en/randomized-trial-of-exercise-and-nutrition-on-chemotherapy-completion-and-pathologic-complete-response-in-women-with-breast-cancer-the-lifestyle-exercise-and-nutrition-early-after-diagnosis-studyra/ 2023-12-11T08:50:50+00:00 https://www.aiom.it/en/a-phase-3-randomized-study-of-atezolizumab-plus-bevacizumab-and-chemotherapy-in-patients-with-egfr-or-alk-mutated-in-non-small-cell-lung-cancer-attlas-kcsg-lu19-04/ 2023-11-30T08:36:54+00:00 https://www.aiom.it/en/sotorasib-plus-panitumumab-in-refractory-colorectal-cancer-with-mutated-kras-g12c/ 2023-11-23T08:25:54+00:00 https://www.aiom.it/en/opioid-induced-neurotoxicity-in-patients-with-cancer-pain/ 2023-11-03T16:11:54+00:00 https://www.aiom.it/en/fruquintinib-versus-placebo-in-patients-with-refractory-metastatic-colorectal-cancer-fresco-2-an-international-multicentre-randomised-double-blind-phase-3-study/ 2023-10-18T14:47:19+00:00 https://www.aiom.it/en/association-between-duration-of-immunotherapy-and-overall-survival-in-advanced-non-small-cell-lung/ 2023-10-13T08:48:36+00:00 https://www.aiom.it/en/risk-of-further-progression-or-death-among-durable-progression-free-survivors-with-melanoma-or-non-small-cell-lung-cancer-in-pd-1-blockade-trials-implications-for-imaging-surveillance/ 2023-10-04T13:27:50+00:00 https://www.aiom.it/en/perioperative-nivolumab-and-chemotherapy-in-stage-iii-non-small-cell-lung-cancer/ 2023-09-13T15:22:24+00:00 https://www.aiom.it/en/trastuzumab-deruxtecan-in-patients-in-the-usa-and-europe-with-her2-positive-advanced-gastric-or-gastroesophageal-junction-cancer-with-disease-progression-on-or-after-a-trastuzumab-containing-regimen/ 2023-07-19T07:44:30+00:00 https://www.aiom.it/en/vorasidenib-in-idh1-or-idh2-mutant-low-grade-glioma/ 2023-07-12T14:05:47+00:00 https://www.aiom.it/en/atezolizumab-plus-cabozantinib-versus-cabozantinib-monotherapy-for-patients-with-renal-cell-carcinoma-after-progression-with-previous-immune-checkpoint-inhibitor-treatment-contact-03-a-multicentre/ 2023-07-12T14:08:05+00:00 https://www.aiom.it/en/temporary-treatment-cessation-versus-continuation-of-first-line-tyrosine-kinase-inhibitor-in-patients-with-advanced-clear-cell-renal-cell-carcinoma-star-an-open-label-non-inferiority-randomised/ 2023-05-24T07:52:59+00:00 https://www.aiom.it/en/trifluridine-tipiracil-and-bevacizumab-in-refractory-metastatic-colorectal-cancer/ 2023-05-17T08:39:19+00:00 https://www.aiom.it/en/panitumumab-vs-bevacizumab-added-to-standard-first-line-chemotherapy-and-overall-survival-among-patients-with-ras-wild-type-left-sided-metastatic-colorectal-cancer-a-randomized-clinical-trial/ 2023-05-10T12:27:51+00:00 https://www.aiom.it/en/pembrolizumab-plus-chemotherapy-in-advanced-endometrial-cancer/ 2023-05-03T13:24:45+00:00 https://www.aiom.it/en/dostarlimab-for-primary-advanced-or-recurrent-endometrial-cancer/ 2023-04-19T09:10:12+00:00 https://www.aiom.it/en/fifteen-year-outcomes-after-monitoring-surgery-or-radiotherapy-for-prostate-cancer/ 2023-04-05T07:40:09+00:00 https://www.aiom.it/en/an-international-open-label-randomised-trial-comparing-a-two-step-approach-versus-the-standard-three-step-approach-of-the-who-analgesic-ladder-in-patients-with-cancer/ 2023-03-29T08:57:51+00:00 https://www.aiom.it/en/lobar-or-sublobar-resection-for-peripheral-stage-ia-non-small-cell-lung-cancer/ 2023-03-22T10:52:41+00:00 https://www.aiom.it/en/rucaparib-or-physicians-choice-in-metastatic-prostate-cancer/ 2023-03-15T08:58:47+00:00 https://www.aiom.it/en/adjuvant-osimertinib-for-resected-egfr-mutated-stage-ib-iiia-non-small-cell-lung-cancer-updated-results-from-the-phase-iii-randomized-adaura-trial/ 2023-03-08T10:52:15+00:00 https://www.aiom.it/en/cancer-in-transgender-and-gender-diverse-persons-a-review/ 2023-03-01T14:27:12+00:00 https://www.aiom.it/en/futibatinib-for-fgfr2-rearranged-intrahepatic-cholangiocarcinoma/ 2023-02-22T10:29:33+00:00 https://www.aiom.it/en/olaparib-efficacy-in-patients-with-metastatic-castration-resistant-prostate-cancer-and-brca1-brca2-or-atm-alterations-identified-by-testing-circulating-tumor-dna/ 2023-02-15T09:33:57+00:00 https://www.aiom.it/en/overall-survival-with-maintenance-olaparib-at-a-7-year-follow-up-in-patients-with-newly-diagnosed-advanced-ovarian-cancer-and-a-brca-mutation-the-solo1-gog-3004-trial/ 2023-02-01T08:43:58+00:00 https://www.aiom.it/en/adagrasib-with-or-without-cetuximab-in-colorectal-cancer-with-mutated-kras-g12c/ 2023-01-25T13:09:38+00:00 https://www.aiom.it/en/pembrolizumab-versus-placebo-as-second-line-therapy-in-patients-from-asia-with-advanced-hepatocellular-carcinoma-a-randomized-double-blind-phase-iii-trial/ 2023-01-11T08:37:02+00:00 https://www.aiom.it/en/overall-survival-with-first-line-atezolizumab-in-combination-with-vemurafenib-and-cobimetinib-in-brafv600-mutation-positive-advanced-melanoma-imspire150-second-interim-analysis-of-a-multicentre-ra/ 2022-12-14T09:05:34+00:00 https://www.aiom.it/en/upfront-folfoxiri-plus-bevacizumab-with-or-without-atezolizumab-in-the-treatment-of-patients-with-metastatic-colorectal-cancer-atezotribe-a-multicentre-open-label-randomised-controlled-phase-2/ 2022-12-12T08:41:22+00:00 https://www.aiom.it/en/effect-of-colonoscopy-screening-on-risks-of-colorectal-cancer-and-related-death/ 2022-12-02T12:09:54+00:00 https://www.aiom.it/en/first-line-avelumab-for-patients-with-pd-l1-positive-metastatic-or-locally-advanced-urothelial-cancer-who-are-unfit-for-cisplatin/ 2022-11-23T09:44:35+00:00 https://www.aiom.it/en/five-year-survival-outcomes-with-nivolumab-plus-ipilimumab-versus-chemotherapy-as-first-line-treatment-for-metastatic-non-small-cell-lung-cancer-in-checkmate-227/ 2022-11-09T09:11:20+00:00 https://www.aiom.it/en/the-time-toxicity-of-cancer-treatment/ 2022-11-04T15:37:17+00:00 https://www.aiom.it/en/neoadjuvant-cemiplimab-for-stage-ii-to-iv-cutaneous-squamous-cell-carcinoma/ 2022-10-19T07:01:12+00:00 https://www.aiom.it/en/addition-of-androgen-receptor-targeted-agents-to-androgen-deprivation-therapy-and-docetaxel-in-metastatic-hormone-sensitive-prostate-cancer-a-systematic-review-and-meta-analysis/ 2022-10-12T13:01:45+00:00 https://www.aiom.it/en/pembrolizumab-versus-placebo-as-adjuvant-therapy-for-completely-resected-stage-ib-iiia-non-small-cell-lung-cancer-pearls-keynote-091-an-interim-analysis-of-a-randomised-triple-blind-phase/ 2022-10-05T13:48:20+00:00 https://www.aiom.it/en/association-of-upfront-peptide-receptor-radionuclide-therapy-with-progression-free-survival-among-patients-with-enteropancreatic-neuroendocrine-tumors/ 2022-09-29T08:25:48+00:00 https://www.aiom.it/en/circulating-tumor-dna-to-guide-rechallenge-with-panitumumab-in-metastatic-colorectal-cancer-the-phase-2-chronos-trial/ 2022-09-21T12:18:08+00:00 https://www.aiom.it/en/long-term-outcomes-and-genetic-predictors-of-response-to-metastasis-directed-therapy-versus-observation-in-oligometastatic-prostate-cancer-analysis-of-stomp-and-oriole-trials/ 2022-09-14T08:48:43+00:00 https://www.aiom.it/en/pembrolizumab-plus-chemotherapy-in-advanced-triple-negative-breast-cancer/ 2022-09-07T15:25:46+00:00 https://www.aiom.it/en/modification-of-the-association-between-frequent-aspirin-use-and-ovarian-cancer-risk-a-meta-analysis-using-individual-level-data-from-two-ovarian-cancer-consortia/ 2022-08-31T07:37:49+00:00 https://www.aiom.it/en/trastuzumab-deruxtecan-in-previously-treated-her2-low-advanced-breast-cancer/ 2022-07-13T08:25:43+00:00 https://www.aiom.it/en/nivolumab-plus-cabozantinib-versus-sunitinib-in-first-line-treatment-for-advanced-renal-cell-carcinoma-checkmate-9er-long-term-follow-up-results-from-an-open-label-randomised-phase-3-trial/ 2022-07-06T07:28:19+00:00 https://www.aiom.it/en/upfront-modified-fluorouracil-leucovorin-oxaliplatin-and-irinotecan-plus-panitumumab-versus-fluorouracil-leucovorin-and-oxaliplatin-plus-panitumumab-for-patients-with-ras-braf-wild-type-metastati/ 2022-06-29T09:45:26+00:00 https://www.aiom.it/en/adebrelimab-or-placebo-plus-carboplatin-and-etoposide-as-first-line-treatment-for-extensive-stage-small-cell-lung-cancer-capstone-1-a-multicentre-randomised-double-blind-placebo-controlled-phas/ 2022-06-15T07:23:28+00:00 https://www.aiom.it/en/final-analysis-of-3-versus-6-months-of-adjuvant-oxaliplatin-and-fluoropyrimidine-based-therapy-in-patients-with-stage-iii-colon-cancer-the-randomized-phase-iii-achieve-trial/ 2022-05-25T07:35:36+00:00 https://www.aiom.it/en/temozolomide-followed-by-combination-with-low-dose-ipilimumab-and-nivolumab-in-patients-with-microsatellite-stable-o-6-methylguanine-dna-methyltransferase-silenced-metastatic-colorectal-cancer-the-m/ 2022-05-18T07:33:29+00:00 https://www.aiom.it/en/neoadjuvant-nivolumab-plus-chemotherapy-in-resectable-lung-cancer/ 2022-05-04T09:27:44+00:00 https://www.aiom.it/en/androgen-deprivation-therapy-use-and-duration-with-definitive-radiotherapy-for-localised-prostate-cancer-an-individual-patient-data-meta-analysis/ 2022-04-27T07:54:11+00:00 https://www.aiom.it/en/trastuzumab-deruxtecan-versus-trastuzumab-emtansine-for-breast-cancer/ 2022-04-22T07:14:31+00:00 https://www.aiom.it/en/nivolumab-plus-chemotherapy-or-ipilimumab-in-gastro-oesophageal-cancer/ 2022-04-13T08:17:46+00:00 https://www.aiom.it/en/darolutamide-and-survival-in-metastatic-hormone-sensitive-prostate-cancer/ 2022-04-06T07:57:52+00:00 https://www.aiom.it/en/aromatase-inhibitors-versus-tamoxifen-in-premenopausal-women-with-oestrogen-receptor-positive-early-stage-breast-cancer-treated-with-ovarian-suppression-a-patient-level-meta-analysis-of-7030-women-fr/ 2022-03-30T07:18:05+00:00 https://www.aiom.it/en/event-free-survival-with-pembrolizumab-in-early-triple-negative-breast-cancer/ 2022-03-23T08:01:38+00:00 https://www.aiom.it/en/final-overall-survival-and-molecular-analysis-in-immotion151-a-phase-3-trial-comparing-atezolizumab-plus-bevacizumab-vs-sunitinib-in-patients-with-previously-untreated-metastatic-renal-cell-carcinoma/ 2022-03-16T07:55:16+00:00 https://www.aiom.it/en/survival-with-cemiplimab-in-recurrent-cervical-cancer/ 2022-03-09T07:52:33+00:00 https://www.aiom.it/en/systemic-therapies-for-preventing-or-treating-aromatase-inhibitor-induced-musculoskeletal-symptoms-in-early-breast-cancer/ 2022-03-02T08:03:34+00:00 https://www.aiom.it/en/neoadjuvant-chemoradiotherapy-versus-upfront-surgery-for-resectable-and-borderline-resectable-pancreatic-cancer-long-term-results-of-the-dutch-randomized-preopanc-trial/ 2022-02-24T08:30:52+00:00 https://www.aiom.it/en/nivolumab-combination-therapy-in-advanced-esophageal-squamous-cell-carcinoma/ 2022-02-16T08:02:36+00:00 https://www.aiom.it/en/cabozantinib-for-radioiodine-refractory-differentiated-thyroid-cancer-cosmic-311-a-randomised-double-blind-placebo-controlled-phase-3-trial/ 2022-02-15T13:48:31+00:00 https://www.aiom.it/en/the-keynote-811-trial-of-dual-pd-1-and-her2-blockade-in-her2-positive-gastric-cancer/ 2022-02-02T07:38:54+00:00 https://www.aiom.it/en/belzutifan-for-renal-cell-carcinoma-in-von-hippel-lindau-disease/ 2022-01-26T08:00:08+00:00 https://www.aiom.it/en/adjuvant-palbociclib-for-early-breast-cancer-the-pallas-trial-results-abcsg-42-aft-05-big-14-03/ 2022-01-19T09:27:21+00:00 https://www.aiom.it/en/maintenance-olaparib-for-patients-with-newly-diagnosed-advanced-ovarian-cancer-and-a-brca-mutation-solo1-gog-3004-5-year-follow-up-of-a-randomized-double-blind-placebo-controlled-phase-3-trial/ 2022-01-12T12:41:13+00:00 https://www.aiom.it/en/lutetium-177-psma-617-for-metastatic-castration-resistant-prostate-cancer/ 2021-12-22T08:07:30+00:00 https://www.aiom.it/en/genomic-profiling-of-lung-adenocarcinoma-in-never-smokers/ 2021-12-15T15:29:20+00:00 https://www.aiom.it/en/uptake-and-survival-outcomes-following-immune-checkpoint-inhibitor-therapy-among-trial-ineligible-patients-with-advanced-solid-cancers/ 2021-12-09T08:32:23+00:00 https://www.aiom.it/en/quality-of-life-in-men-with-prostate-cancer-randomly-allocated-to-receive-docetaxel-or-abiraterone-in-the-stampede-trial/ 2021-12-01T08:09:32+00:00 https://www.aiom.it/en/gemcitabine-plus-cisplatin-versus-fluorouracil-plus-cisplatin-as-first-line-therapy-for-recurrent-or-metastatic-nasopharyngeal-carcinoma-final-overall-survival-analysis-of-gem20110714-phase-iii-study/ 2021-11-17T08:16:07+00:00 https://www.aiom.it/en/extended-therapy-with-letrozole-as-adjuvant-treatment-of-postmenopausal-patients-with-early-stage-breast-cancer-a-multicentre-open-label-randomised-phase-3-trial/ 2021-11-10T08:25:38+00:00 https://www.aiom.it/en/pembrolizumab-for-persistent-recurrent-or-metastatic-cervical-cancer/ 2021-11-03T14:37:29+00:00 https://www.aiom.it/en/cetuximab-rechallenge-plus-avelumab-in-pretreated-patients-with-ras-wild-type-metastatic-colorectal-cancer-the-phase-2-single-arm-clinical-cave-trial/ 2021-10-20T08:10:28+00:00 https://www.aiom.it/en/benefits-and-harms-of-lung-cancer-screening-by-chest-computed-tomography-a-systematic-review-and-meta-analysis/ 2021-10-06T09:21:17+00:00 https://www.aiom.it/en/adjuvant-atezolizumab-after-adjuvant-chemotherapy-in-resected-stage-ib-iiia-non-small-cell-lung-cancer-impower010-a-randomised-multicentre-open-label-phase-3-trial/ 2021-09-29T06:51:20+00:00 https://www.aiom.it/en/gemcitabine-with-or-without-ramucirumab-as-second-line-treatment-for-malignant-pleural-mesothelioma-rames-a-randomised-double-blind-placebo-controlled-phase-2-trial/ 2021-09-22T10:03:20+00:00 https://www.aiom.it/en/adjuvant-pembrolizumab-after-nephrectomy-in-renal-cell-carcinoma/ 2021-09-15T09:37:49+00:00 https://www.aiom.it/en/nivolumab-plus-ipilimumab-vs-nivolumab-for-previously-treated-patients-with-stage-iv-squamous-cell-lung-cancer-the-lung-map-s1400i-phase-3-randomized-clinical-trial/ 2021-09-08T07:01:46+00:00 https://www.aiom.it/en/pregnancy-after-breast-cancer-a-systematic-review-and-meta-analysis/ 2021-07-28T08:06:56+00:00 https://www.aiom.it/en/intracranial-and-extracranial-efficacy-of-lorlatinib-in-patients-with-alk-positive-non-small-cell-lung-cancer-previously-treated-with-second-generation-alk-tkis/ 2021-07-21T07:15:52+00:00 https://www.aiom.it/en/cancer-immunotherapy-in-special-challenging-populations-recommendations-of-the-advisory-committee-of-spanish-melanoma-group-gem/ 2021-07-14T09:57:46+00:00 https://www.aiom.it/en/sotorasib-for-lung-cancers-with-kras-p-g12c-mutation/ 2021-06-30T07:09:57+00:00 https://www.aiom.it/en/adjuvant-olaparib-for-patients-with-brca1-or-brca2-mutated-breast-cancer/ 2021-06-23T11:41:08+00:00 https://www.aiom.it/en/adjuvant-nivolumab-versus-placebo-in-muscle-invasive-urothelial-carcinoma/ 2021-06-16T10:34:59+00:00 https://www.aiom.it/en/influenza-vaccine-indication-during-therapy-with-immune-checkpoint-inhibitors-a-multicenter-prospective-observational-study-invidia-2/ 2021-06-10T12:55:05+00:00 https://www.aiom.it/en/patient-reported-outcomes-predict-progression-free-survival-of-patients-with-advanced-breast-cancer-treated-with-abemaciclib/ 2021-06-03T08:13:14+00:00 https://www.aiom.it/en/high-tumor-mutation-burden-fails-to-predict-immune-checkpoint-blockade-response-across-all-cancer-types/ 2021-05-26T11:29:07+00:00 https://www.aiom.it/en/sacituzumab-govitecan-in-metastatic-triple-negative-breast-cancer/ 2021-05-19T08:17:10+00:00 https://www.aiom.it/en/effects-of-mindfulness-based-interventions-on-fatigue-in-cancer-survivors-a-systematic-review-and-meta-analysis-of-randomized-controlled-trials/ 2021-05-12T07:18:43+00:00 https://www.aiom.it/en/70-gene-signature-as-an-aid-for-treatment-decisions-in-early-breast-cancer-updated-results-of-the-phase-3-randomised-mindact-trial-with-an-exploratory-analysis-by-age/ 2021-05-05T07:12:52+00:00 https://www.aiom.it/en/updated-integrated-analysis-of-the-efficacy-and-safety-of-entrectinib-in-locally-advanced-or-metastatic-ros1-fusion-positive-non-small-cell-lung-cancer/ 2021-04-28T07:37:48+00:00 https://www.aiom.it/en/primary-tumor-resection-plus-chemotherapy-versus-chemotherapy-alone-for-colorectal-cancer-patients-with-asymptomatic-synchronous-unresectable-metastases-jcog1007-ipacs-a-randomized-clinical-trial/ 2021-03-31T06:41:06+00:00 https://www.aiom.it/en/nivolumab-plus-cabozantinib-versus-sunitinib-for-advanced-renal-cell-carcinoma/ 2021-03-24T10:29:01+00:00 https://www.aiom.it/en/enfortumab-vedotin-in-previously-treated-advanced-urothelial-carcinoma/ 2021-03-17T11:58:22+00:00 https://www.aiom.it/en/breast-cancer-risk-genes-association-analysis-in-more-than-113000-women/ 2021-03-10T11:01:53+00:00 https://www.aiom.it/en/alpelisib-plus-fulvestrant-for-pik3ca-mutated-hormone-receptor-positive-human-epidermal-growth-factor-receptor-2-negative-advanced-breast-cancer-final-overall-survival-results-from-solar-1/ 2021-03-03T12:53:36+00:00 https://www.aiom.it/en/first-line-nivolumab-plus-ipilimumab-combined-with-two-cycles-of-chemotherapy-in-patients-with-non-small-cell-lung-cancer-checkmate-9la-an-international-randomised-open-label-phase-3-trial/ 2021-02-24T10:07:17+00:00 https://www.aiom.it/en/continuous-versus-1-year-fixed-duration-nivolumab-in-previously-treated-advanced-non-small-cell-lung-cancer-checkmate-153/ 2021-02-17T09:03:37+00:00 https://www.aiom.it/en/first-line-nivolumab-plus-ipilimumab-in-unresectable-malignant-pleural-mesothelioma-checkmate-743-a-multicentre-randomised-open-label-phase-3-trial/ 2021-02-10T11:06:31+00:00 https://www.aiom.it/en/short-course-radiotherapy-followed-by-chemotherapy-before-total-mesorectal-excision-tme-versus-preoperative-chemoradiotherapy-tme-and-optional-adjuvant-chemotherapy-in-locally-advanced-rectal-canc/ 2021-02-03T10:59:14+00:00 https://www.aiom.it/en/gefitinib-versus-vinorelbine-plus-cisplatin-as-adjuvant-treatment-for-stage-ii-iiia-n1-n2-egfr-mutant-nsclc-final-overall-survival-analysis-of-ctong1104-phase-iii-trial/ 2021-01-27T14:16:56+00:00 https://www.aiom.it/en/durvalumab-with-or-without-tremelimumab-plus-platinum-etoposide-versus-platinum-etoposide-alone-in-first-line-treatment-of-extensive-stage-small-cell-lung-cancer-caspian-updated-r/ 2021-01-21T15:52:29+00:00 https://www.aiom.it/en/pembrolizumab-in-microsatellite-instability-high-advanced-colorectal-cancer/ 2021-01-13T07:49:16+00:00 https://www.aiom.it/en/addition-of-chemotherapy-to-local-therapy-in-women-aged-70-years-or-older-with-triple-negative-breast-cancer-a-propensity-matched-analysis/ 2020-12-16T08:11:51+00:00 https://www.aiom.it/en/pembrolizumab-plus-axitinib-versus-sunitinib-monotherapy-as-first-line-treatment-of-advanced-renal-cell-carcinoma-keynote-426-extended-follow-up-from-a-randomised-open-label-phase-3-trial/ 2020-12-02T08:59:22+00:00 https://www.aiom.it/en/patient-associations-and-clinical-oncology-research-how-much-does-a-patients-voice-really-matter/ 2020-11-26T09:18:16+00:00 https://www.aiom.it/en/abemaciclib-combined-with-endocrine-therapy-for-the-adjuvant-treatment-of-hr-her2-node-positive-high-risk-early-breast-cancer-monarche/ 2020-11-18T09:04:52+00:00 https://www.aiom.it/en/veliparib-with-carboplatin-and-paclitaxel-in-brca-mutated-advanced-breast-cancer-brocade3-a-randomised-double-blind-placebo-controlled-phase-3-trial/ 2020-11-11T08:05:56+00:00 https://www.aiom.it/en/hpv-vaccination-and-the-risk-of-invasive-cervical-cancer/ 2020-11-04T17:31:55+00:00 https://www.aiom.it/en/survival-with-olaparib-in-metastatic-castration-resistant-prostate-cancer/ 2020-10-29T09:20:09+00:00 https://www.aiom.it/en/osimertinib-in-resected-egfr-mutated-non-small-cell-lung-cancer/ 2020-10-21T07:29:25+00:00 https://www.aiom.it/en/personalized-circulating-tumor-dna-analysis-as-a-predictive-biomarker-in-solid-tumor-patients-treated-with-pembrolizumab/ 2020-10-07T07:31:24+00:00 https://www.aiom.it/en/efficacy-and-safety-of-pembrolizumab-or-pembrolizumab-plus-chemotherapy-vs-chemotherapy-alone-for-patients-with-first-line-advanced-gastric-cancer-the-keynote-062-phase-3-randomized-clinical-trial/ 2020-09-23T09:57:03+00:00 https://www.aiom.it/en/capmatinib-in-met-exon-14-mutated-or-met-amplified-non-small-cell-lung-cancer/ 2020-09-16T09:38:44+00:00 https://www.aiom.it/en/efficacy-of-selpercatinib-in-ret-fusion-positive-non-small-cell-lung-cancer/ 2020-09-09T07:40:35+00:00 https://www.aiom.it/en/ripretinib-in-patients-with-advanced-gastrointestinal-stromal-tumours-invictus-a-double-blind-randomised-placebo-controlled-phase-3-trial/ 2020-09-02T06:58:14+00:00 https://www.aiom.it/en/pregnancy-after-breast-cancer-in-patients-with-germline-brca-mutations/ 2020-07-29T12:08:43+00:00 https://www.aiom.it/en/prognostic-value-of-her2-status-on-circulating-tumor-cells-in-advanced-stage-breast-cancer-patients-with-her2-negative-tumors/ 2020-07-22T07:23:59+00:00 https://www.aiom.it/en/serum-detection-of-nonadherence-to-adjuvant-tamoxifen-and-breast-cancer-recurrence-risk/ 2020-07-16T08:12:46+00:00 https://www.aiom.it/en/atezolizumab-vemurafenib-and-cobimetinib-as-first-line-treatment-for-unresectable-advanced-brafv600-mutation-positive-melanoma-imspire150-primary-analysis-of-the-randomised-double-blind-placebo/ 2020-07-08T07:51:01+00:00 https://www.aiom.it/en/cancer-risk-following-lymphoid-malignancies-among-hiv-infected-people/ 2020-07-01T07:00:27+00:00 https://www.aiom.it/en/olaparib-for-metastatic-castration-resistant-prostate-cancer/ 2020-06-23T15:46:31+00:00 https://www.aiom.it/en/tepotinib-in-non-small-cell-lung-cancer-with-met-exon-14-skipping-mutations/ 2020-06-17T08:01:37+00:00 https://www.aiom.it/en/atezolizumab-plus-bevacizumab-in-unresectable-hepatocellular-carcinoma/ 2020-06-04T07:04:10+00:00 https://www.aiom.it/en/covid-19-emergency-and-the-need-to-speed-up-the-adoption-of-electronic-patient-reported-outcomes-in-cancer-clinical-practice/ 2020-05-27T07:32:29+00:00 https://www.aiom.it/en/the-use-of-not-negative-conclusions-to-describe-results-of-formally-negative-trials-presented-at-oncology-meetings/ 2020-05-20T13:39:31+00:00 https://www.aiom.it/en/pertuzumab-trastuzumab-and-docetaxel-for-her2-positive-metastatic-breast-cancer-cleopatra-end-of-study-results-from-a-double-blind-randomised-placebo-controlled-phase-3-study/ 2020-04-30T08:24:08+00:00 https://www.aiom.it/en/sensitive-and-specific-multi-cancer-detection-and-localization-using-methylation-signatures-in-cell-free-dna/ 2020-04-15T09:17:33+00:00 https://www.aiom.it/en/patient-reported-outcomes-following-pembrolizumab-or-placebo-plus-pemetrexed-and-platinum-in-patients-with-previously-untreated-metastatic-non-squamous-non-small-cell-lung-cancer-keynote-189-a-mu/ 2020-04-08T09:40:53+00:00 https://www.aiom.it/en/cancer-care-during-the-spread-of-coronavirus-disease-2019-covid-19-in-italy-young-oncologists-perspective/ 2020-03-31T15:01:33+00:00 https://www.aiom.it/en/the-treatment-of-cancer-patients-during-covid19-pandemia/ 2020-03-27T10:48:14+00:00 https://www.aiom.it/en/preoperative-chemoradiotherapy-versus-immediate-surgery-for-resectable-and-borderline-resectable-pancreatic-cancer-results-of-the-dutch-randomized-phase-iii-preopanc-trial/ 2020-03-25T07:47:40+00:00 https://www.aiom.it/en/systemic-chemotherapy-with-or-without-cetuximab-in-patients-with-resectable-colorectal-liver-metastasis-new-epoc-long-term-results-of-a-multicentre-randomised-controlled-phase-3-trial/ 2020-03-04T10:45:46+00:00 https://www.aiom.it/en/clinical-cancer-advances-2020-annual-report-on-progress-against-cancer-from-the-american-society-of-clinical-oncology/ 2020-02-26T08:13:16+00:00 https://www.aiom.it/en/the-role-of-maintenance-strategies-in-metastatic-colorectal-cancer-a-systematic-review-and-network-meta-analysis-of-randomized-clinical-trials/ 2020-02-19T12:13:10+00:00 https://www.aiom.it/en/reduced-lung-cancer-mortality-with-volume-ct-screening-in-a-randomized-trial/ 2020-02-13T09:17:01+00:00 https://www.aiom.it/en/effects-of-intermittent-fasting-on-health-aging-and-disease/ 2020-02-05T08:32:28+00:00 https://www.aiom.it/en/lorlatinib-in-advanced-ros1-positive-non-small-cell-lung-cancer-a-multicentre-open-label-single-arm-phase-1-2-trial/ 2020-01-29T09:20:52+00:00 https://www.aiom.it/en/olaparib-plus-bevacizumab-as-first-line-maintenance-in-ovarian-cancer/ 2020-01-22T09:36:05+00:00 https://www.aiom.it/en/individual-patient-data-meta-analysis-of-the-value-of-microsatellite-instability-as-a-biomarker-in-gastric-cancer/ 2020-01-15T08:19:14+00:00 https://www.aiom.it/en/encorafenib-binimetinib-and-cetuximab-in-braf-v600e-mutated-colorectal-cancer/ 2020-01-09T15:02:21+00:00 https://www.aiom.it/en/daily-press-review-145/ 2019-12-20T09:34:49+00:00 https://www.aiom.it/en/hype-or-hope-the-strange-case-of-platinum-salts-renaissance-in-breast-cancer/ 2019-12-20T09:30:14+00:00 https://www.aiom.it/en/daily-press-review-144/ 2019-12-19T08:36:04+00:00 https://www.aiom.it/en/daily-press-review-143/ 2019-12-18T09:24:11+00:00 https://www.aiom.it/en/daily-press-review-142/ 2019-12-17T08:30:17+00:00 https://www.aiom.it/en/daily-press-review-139/ 2019-12-16T12:45:47+00:00 https://www.aiom.it/en/daily-press-review-140/ 2019-12-16T12:49:19+00:00 https://www.aiom.it/en/daily-press-review-141/ 2019-12-16T12:52:20+00:00 https://www.aiom.it/en/evaluation-of-pole-and-pold1-mutations-as-biomarkers-for-immunotherapy-outcomes-across-multiple-cancer-types/ 2019-12-13T09:00:41+00:00 https://www.aiom.it/en/daily-press-review-138/ 2019-12-13T08:58:56+00:00 https://www.aiom.it/en/daily-press-review-137/ 2019-12-12T08:55:18+00:00 https://www.aiom.it/en/daily-press-review-136/ 2019-12-11T09:01:30+00:00 https://www.aiom.it/en/daily-press-review-135/ 2019-12-10T09:05:10+00:00 https://www.aiom.it/en/daily-press-review-132/ 2019-12-09T09:13:45+00:00 https://www.aiom.it/en/daily-press-review-133/ 2019-12-09T09:16:32+00:00 https://www.aiom.it/en/daily-press-review-134/ 2019-12-09T09:19:08+00:00 https://www.aiom.it/en/developing-a-highly-specific-biomarker-for-germ-cell-malignancies-plasma-mir371-expression-across-the-germ-cell-malignancy-spectrum/ 2019-11-26T10:20:15+00:00 https://www.aiom.it/en/daily-press-review-131/ 2019-12-06T09:00:51+00:00 https://www.aiom.it/en/daily-press-review-130/ 2019-12-04T14:13:35+00:00 https://www.aiom.it/en/daily-press-review-129/ 2019-12-03T08:55:27+00:00 https://www.aiom.it/en/daily-press-review-128/ 2019-12-02T15:34:12+00:00 https://www.aiom.it/en/daily-press-review-127/ 2019-12-02T15:33:57+00:00 https://www.aiom.it/en/daily-press-review-126/ 2019-12-02T15:33:06+00:00 https://www.aiom.it/en/daily-press-review-125/ 2019-11-29T09:05:27+00:00 https://www.aiom.it/en/daily-press-review-124/ 2019-11-29T09:07:14+00:00 https://www.aiom.it/en/daily-press-review-123/ 2019-11-29T09:06:54+00:00 https://www.aiom.it/en/daily-press-review-122/ 2019-11-26T08:40:40+00:00 https://www.aiom.it/en/daily-press-review-121/ 2019-11-25T15:17:45+00:00 https://www.aiom.it/en/the-frequency-and-prognostic-significance-of-the-histologic-type-in-early-stage-ovarian-carcinoma-a-reclassification-study-by-the-spanish-group-for-ovarian-cancer-research-geico/ 2019-11-26T09:58:51+00:00 https://www.aiom.it/en/daily-press-review-120/ 2019-11-25T15:17:30+00:00 https://www.aiom.it/en/daily-press-review-119/ 2019-11-25T15:16:58+00:00 https://www.aiom.it/en/daily-press-review-118/ 2019-11-22T09:42:15+00:00 https://www.aiom.it/en/daily-press-review-117/ 2019-11-21T08:54:15+00:00 https://www.aiom.it/en/daily-press-review-116/ 2019-11-20T08:38:18+00:00 https://www.aiom.it/en/daily-press-review-115/ 2019-11-19T10:05:55+00:00 https://www.aiom.it/en/daily-press-review-113/ 2019-11-18T09:35:06+00:00 https://www.aiom.it/en/noninvasive-detection-of-microsatellite-instability-and-high-tumor-mutation-burden-in-cancer-patients-treated-with-pd-1-blockade/ 2019-11-14T09:35:10+00:00 https://www.aiom.it/en/daily-press-review-114/ 2019-11-18T09:40:18+00:00 https://www.aiom.it/en/daily-press-review-112/ 2019-11-18T09:42:04+00:00 https://www.aiom.it/en/daily-press-review-111/ 2019-11-15T08:42:05+00:00 https://www.aiom.it/en/daily-press-review-110/ 2019-11-14T09:43:06+00:00 https://www.aiom.it/en/daily-press-review-109/ 2019-11-14T08:29:26+00:00 https://www.aiom.it/en/working-group-oncology-nursing/ 2019-11-18T14:32:38+00:00 https://www.aiom.it/en/young-oncologists-working-group/ 2019-11-12T13:15:13+00:00 https://www.aiom.it/en/clinical-research-coordinators-working-group/ 2019-11-12T13:04:34+00:00 https://www.aiom.it/en/board-of-directors/ 2019-11-12T12:13:08+00:00 https://www.aiom.it/en/aiom-regional-sections/ 2019-11-12T12:03:14+00:00 https://www.aiom.it/en/daily-press-review-107/ 2019-11-12T09:58:31+00:00 https://www.aiom.it/en/daily-press-review-108/ 2019-11-12T09:59:50+00:00 https://www.aiom.it/en/association-of-early-palliative-care-use-with-survival-and-place-of-death-among-patients-with-advanced-lung-cancer-receiving-care-in-the-veterans-health-administration/ 2019-11-14T09:17:49+00:00 https://www.aiom.it/en/daily-press-review-105/ 2019-11-11T15:22:12+00:00 https://www.aiom.it/en/daily-press-review-106/ 2019-11-11T15:25:14+00:00 https://www.aiom.it/en/daily-press-review-104/ 2019-11-08T08:49:52+00:00 https://www.aiom.it/en/daily-press-review-103/ 2019-11-07T09:12:23+00:00 https://www.aiom.it/en/daily-press-review-102/ 2019-11-06T08:56:32+00:00 https://www.aiom.it/en/daily-press-review-101/ 2019-11-05T09:14:48+00:00 https://www.aiom.it/en/niraparib-maintenance-therapy-in-patients-with-recurrent-ovarian-cancer-after-a-partial-response-to-the-last-platinum-based-chemotherapy-in-the-engot-ov16-nova-trial/ 2019-11-14T09:15:52+00:00 https://www.aiom.it/en/daily-press-review-99/ 2019-11-04T13:26:59+00:00 https://www.aiom.it/en/daily-press-review-100/ 2019-11-04T13:28:50+00:00 https://www.aiom.it/en/daily-press-review-98/ 2019-11-04T13:25:42+00:00 https://www.aiom.it/en/daily-press-review-97/ 2019-10-31T08:54:44+00:00 https://www.aiom.it/en/lung-cancer-and-end-of-life-care-a-systematic-review-and-thematic-synthesis-of-aggressive-inpatient-care/ 2019-10-21T09:26:14+00:00 https://www.aiom.it/en/daily-press-review-96/ 2019-10-30T08:51:21+00:00 https://www.aiom.it/en/daily-press-review-95/ 2019-10-29T08:36:44+00:00 https://www.aiom.it/en/daily-press-review-94/ 2019-10-26T14:27:07+00:00 https://www.aiom.it/en/daily-press-review-93/ 2019-10-25T10:20:36+00:00 https://www.aiom.it/en/daily-press-review-92/ 2019-10-25T10:19:44+00:00 https://www.aiom.it/en/safety-of-pregnancy-following-breast-cancer-bc-in-patients-pts-carrying-a-brca-mutation-mbrca-results-of-an-international-cohort-study/ 2019-10-23T08:01:19+00:00 https://www.aiom.it/en/daily-press-review-91/ 2019-10-23T07:57:34+00:00 https://www.aiom.it/en/daily-press-review-90/ 2019-10-22T08:29:34+00:00 https://www.aiom.it/en/daily-press-review-87/ 2019-10-21T08:26:37+00:00 https://www.aiom.it/en/daily-press-review-88/ 2019-10-21T08:28:56+00:00 https://www.aiom.it/en/daily-press-review-89/ 2019-10-21T08:32:47+00:00 https://www.aiom.it/en/first-line-immuno-oncology-combination-therapies-in-metastatic-renal-cell-carcinoma-results-from-the-international-metastatic-renal-cell-carcinoma-database-consortium/ 2019-10-18T12:24:27+00:00 https://www.aiom.it/en/daily-press-review-86/ 2019-10-18T12:17:04+00:00 https://www.aiom.it/en/daily-press-review-85/ 2019-10-17T12:49:46+00:00 https://www.aiom.it/en/daily-press-review-84/ 2019-10-16T07:37:43+00:00 https://www.aiom.it/en/daily-press-review-83/ 2019-10-15T07:41:26+00:00 https://www.aiom.it/en/daily-press-review-82/ 2019-10-14T09:30:34+00:00 https://www.aiom.it/en/daily-press-review-81/ 2019-10-14T09:25:39+00:00 https://www.aiom.it/en/fear-of-cancer-recurrence-a-model-examination-of-physical-symptoms-emotional-distress-and-health-behavior-change/ 2019-10-14T09:41:14+00:00 https://www.aiom.it/en/daily-press-review-80/ 2019-10-11T08:27:19+00:00 https://www.aiom.it/en/daily-press-review-79/ 2019-10-10T08:17:59+00:00 https://www.aiom.it/en/daily-press-review-78/ 2019-10-09T08:42:15+00:00 https://www.aiom.it/en/daily-press-review-77/ 2019-10-08T10:26:31+00:00 https://www.aiom.it/en/has-the-quality-of-patient-provider-communication-about-survivorship-care-improved/ 2019-10-09T09:37:15+00:00 https://www.aiom.it/en/daily-press-review-74/ 2019-10-07T08:06:59+00:00 https://www.aiom.it/en/daily-press-review-75/ 2019-10-07T08:08:05+00:00 https://www.aiom.it/en/daily-press-review-76/ 2019-10-07T08:09:06+00:00 https://www.aiom.it/en/daily-press-review-73/ 2019-10-04T09:20:55+00:00 https://www.aiom.it/en/daily-press-review-72/ 2019-10-03T08:43:30+00:00 https://www.aiom.it/en/daily-press-review-71/ 2019-10-02T09:13:51+00:00 https://www.aiom.it/en/daily-press-review-70/ 2019-10-01T08:54:17+00:00 https://www.aiom.it/en/efficacy-and-safety-results-from-geico-1205-a-randomized-phase-ii-trial-of-neoadjuvant-chemotherapy-with-or-without-bevacizumab-for-advanced-epithelial-ovarian-cancer/ 2019-10-07T13:27:31+00:00 https://www.aiom.it/en/daily-press-review-69/ 2019-09-30T09:04:07+00:00 https://www.aiom.it/en/daily-press-review-68/ 2019-09-29T11:00:19+00:00 https://www.aiom.it/en/daily-press-review-67/ 2019-09-28T11:44:26+00:00 https://www.aiom.it/en/daily-press-review-66/ 2019-09-27T08:58:21+00:00 https://www.aiom.it/en/daily-press-review-54/ 2019-09-26T09:55:15+00:00 https://www.aiom.it/en/daily-press-review-65/ 2019-09-26T09:53:02+00:00 https://www.aiom.it/en/daily-press-review-64/ 2019-09-26T09:53:11+00:00 https://www.aiom.it/en/cost-effectiveness-of-multigene-panel-sequencing-for-patients-with-advanced-non-small-cell-lung-cancer/ 2019-10-07T09:58:37+00:00 https://www.aiom.it/en/daily-press-review-63/ 2019-09-26T09:53:20+00:00 https://www.aiom.it/en/daily-press-review-62/ 2019-09-26T09:53:27+00:00 https://www.aiom.it/en/daily-press-review-61/ 2019-09-26T09:53:35+00:00 https://www.aiom.it/en/daily-press-review-60/ 2019-09-26T09:53:43+00:00 https://www.aiom.it/en/daily-press-review-59/ 2019-09-26T09:53:53+00:00 https://www.aiom.it/en/daily-press-review-58/ 2019-09-26T09:54:05+00:00 https://www.aiom.it/en/daily-press-review-57/ 2019-09-26T09:54:13+00:00 https://www.aiom.it/en/will-that-pulmonary-nodule-become-cancerous-a-risk-prediction-model-for-incident-lung-cancer/ 2019-09-26T10:37:35+00:00 https://www.aiom.it/en/daily-press-review-56/ 2019-09-26T09:54:20+00:00 https://www.aiom.it/en/daily-press-review-55/ 2019-09-26T09:54:29+00:00 https://www.aiom.it/en/the-holy-father-francesco-received-in-audience-the-members-of-the-italian-association-of-medical-oncology-aiom/ 2019-09-26T08:09:37+00:00 https://www.aiom.it/en/neoadjuvant-three-dimensional-conformal-radiotherapy-for-resectable-hepatocellular-carcinoma-with-portal-vein-tumor-thrombus-a-randomized-open-label-multicenter-controlled-study/ 2019-09-26T10:37:01+00:00 https://www.aiom.it/en/daily-press-review-53/ 2019-09-09T08:19:06+00:00 https://www.aiom.it/en/daily-press-review-52/ 2019-09-04T08:04:46+00:00 https://www.aiom.it/en/daily-press-review-51/ 2019-09-03T09:09:21+00:00 https://www.aiom.it/en/daily-press-review-50/ 2019-08-28T08:30:05+00:00 https://www.aiom.it/en/daily-press-review-49/ 2019-08-27T08:23:22+00:00 https://www.aiom.it/en/pembrolizumab-in-men-with-heavily-treated-metastatic-castrate-resistant-prostate-cancer/ 2019-09-26T10:36:44+00:00 https://www.aiom.it/en/development-and-validation-of-a-prognostic-nomogram-for-overall-survival-in-patients-with-platinum-resistant-ovarian-cancer-treated-with-chemotherapy/ 2019-09-26T10:48:39+00:00 https://www.aiom.it/en/daily-press-review-48/ 2019-08-01T12:13:53+00:00 https://www.aiom.it/en/daily-press-review-47/ 2019-07-30T07:48:47+00:00 https://www.aiom.it/en/daily-press-review-46/ 2019-07-29T10:13:37+00:00 https://www.aiom.it/en/daily-press-review-45/ 2019-07-26T09:02:58+00:00 https://www.aiom.it/en/daily-press-review-44/ 2019-07-25T08:59:03+00:00 https://www.aiom.it/en/daily-press-review-43/ 2019-07-24T07:45:16+00:00 https://www.aiom.it/en/daily-press-review-42/ 2019-07-23T08:59:17+00:00 https://www.aiom.it/en/daily-press-review-41/ 2019-07-19T08:33:06+00:00 https://www.aiom.it/en/daily-press-review-40/ 2019-07-18T12:13:06+00:00 https://www.aiom.it/en/daily-press-review-39/ 2019-07-17T07:47:58+00:00 https://www.aiom.it/en/daily-press-review-38/ 2019-07-16T07:37:35+00:00 https://www.aiom.it/en/daily-press-review-37/ 2019-07-15T10:16:55+00:00 https://www.aiom.it/en/daily-press-review-36/ 2019-07-15T10:13:23+00:00 https://www.aiom.it/en/daily-press-review-35/ 2019-07-15T10:12:16+00:00 https://www.aiom.it/en/daily-press-review-34/ 2019-07-12T08:21:30+00:00 https://www.aiom.it/en/daily-press-review-33/ 2019-07-11T08:44:22+00:00 https://www.aiom.it/en/daily-press-review-32/ 2019-07-10T07:42:40+00:00 https://www.aiom.it/en/daily-press-review-31/ 2019-07-09T13:42:33+00:00 https://www.aiom.it/en/daily-press-review-30/ 2019-07-04T09:30:46+00:00 https://www.aiom.it/en/daily-press-review-29/ 2019-07-03T10:58:15+00:00 https://www.aiom.it/en/daily-press-review-28/ 2019-06-25T08:20:01+00:00 https://www.aiom.it/en/daily-press-review-27/ 2019-06-24T08:41:14+00:00 https://www.aiom.it/en/daily-press-review-26/ 2019-06-24T08:39:50+00:00 https://www.aiom.it/en/daily-press-review-25/ 2019-06-24T08:38:37+00:00 https://www.aiom.it/en/daily-press-review-24/ 2019-06-21T12:58:20+00:00 https://www.aiom.it/en/daily-press-review-23/ 2019-06-20T10:27:08+00:00 https://www.aiom.it/en/daily-press-review-22/ 2019-06-19T08:16:50+00:00 https://www.aiom.it/en/daily-press-review-21/ 2019-06-18T07:43:47+00:00 https://www.aiom.it/en/daily-press-review-18/ 2019-06-17T14:32:46+00:00 https://www.aiom.it/en/daily-press-review-19/ 2019-06-17T14:38:17+00:00 https://www.aiom.it/en/daily-press-review-20/ 2019-06-17T14:39:41+00:00 https://www.aiom.it/en/daily-press-review-17/ 2019-06-14T07:47:38+00:00 https://www.aiom.it/en/daily-press-news-3/ 2019-06-17T14:41:09+00:00 https://www.aiom.it/en/daily-press-review-16/ 2019-06-12T07:59:14+00:00 https://www.aiom.it/en/daily-press-review-15/ 2019-06-11T07:55:23+00:00 https://www.aiom.it/en/daily-press-review-14/ 2019-06-11T07:05:22+00:00 https://www.aiom.it/en/daily-press-review-13/ 2019-06-11T07:04:12+00:00 https://www.aiom.it/en/daily-press-review-12/ 2019-06-11T07:00:43+00:00 https://www.aiom.it/en/daily-press-review-11/ 2019-06-07T09:03:08+00:00 https://www.aiom.it/en/daily-press-review-10/ 2019-06-06T07:22:03+00:00 https://www.aiom.it/en/daily-press-review-9/ 2019-06-05T08:17:35+00:00 https://www.aiom.it/en/daily-press-review-8/ 2019-06-04T08:33:07+00:00 https://www.aiom.it/en/daily-press-review-6/ 2019-06-04T07:00:51+00:00 https://www.aiom.it/en/daily-press-news-2/ 2019-06-04T07:05:19+00:00 https://www.aiom.it/en/daily-press-review-7/ 2019-06-04T07:07:06+00:00 https://www.aiom.it/en/daily-press-review-5/ 2019-05-31T09:16:33+00:00 https://www.aiom.it/en/daily-press-news/ 2019-05-31T09:17:36+00:00 https://www.aiom.it/en/daily-press-review-4/ 2019-05-29T10:57:24+00:00 https://www.aiom.it/en/pembrolizumab-plus-chemotherapy-for-squamous-non-small-cell-lung-cancer/ 2019-09-26T10:23:48+00:00 https://www.aiom.it/en/press-review-2/ 2019-05-29T10:14:17+00:00 https://www.aiom.it/en/2019-precision-oncology/ 2019-06-05T07:27:43+00:00 https://www.aiom.it/en/daily-press-review/ 2019-05-29T10:14:07+00:00 https://www.aiom.it/en/press-review/ 2019-05-29T10:14:07+00:00 https://www.aiom.it/en/daily-press-review-3/ 2019-05-29T10:13:56+00:00 https://www.aiom.it/en/daily-press-review-2/ 2019-05-29T10:14:05+00:00 https://www.aiom.it/en/past-presidents/ 2019-11-12T11:26:30+00:00 https://www.aiom.it/en/founding-members/ 2019-09-25T08:52:00+00:00 https://www.aiom.it/en/aiom-2018-colorectal-tumours-guidelines/ 2019-09-25T10:44:55+00:00 https://www.aiom.it/en/aiom-2018-breast-neoplasms-guidelines/ 2019-09-25T10:44:48+00:00 https://www.aiom.it/en/aiom-official-journals/ 2023-04-07T11:20:25+00:00 https://www.aiom.it/en/maintenance-olaparib-in-patients-with-newly-diagnosed-advanced-ovarian-cancer/ 2019-05-28T08:16:22+00:00 https://www.aiom.it/en/questioning-the-value-of-fluorodeoxyglucose-positron-emission-tomography-for-residual-lesions-after-chemotherapy-for-metastatic-seminoma-results-of-an-international-global-germ-cell-cancer-group-regi/ 2019-09-26T10:34:26+00:00 https://www.aiom.it/en/gratitude-and-blessings-italian-oncologists-present-at-a-papal-audience/ 2019-05-29T10:54:56+00:00